Lynx1 Capital buys Neuphoria Therapeutics (NEUP) shares worth $3.28m
PositiveFinancial Markets

Lynx1 Capital has made a significant investment by purchasing shares of Neuphoria Therapeutics worth $3.28 million. This move highlights Lynx1's confidence in Neuphoria's potential in the therapeutic market, which could lead to exciting developments in healthcare. Such investments not only bolster the companies involved but also signal to investors that innovative solutions in therapeutics are gaining traction.
— Curated by the World Pulse Now AI Editorial System









